Traws Pharma Inc (TRAW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of -4.438x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.50 Million) by net assets ($1.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Traws Pharma Inc worth for the company's overall valuation and market capitalisation.
Traws Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Traws Pharma Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wahana Inti MakmurTbk PT
JK:NASI
|
-0.016x |
|
FELIX Group Holdings Ltd
AU:FLX
|
-0.310x |
|
Thriven Global Bhd
KLSE:7889
|
0.067x |
|
Kaili Resources Ltd
AU:KLR
|
0.016x |
|
Senti Biosciences Inc
NASDAQ:SNTI
|
-1.163x |
|
Jcurve Solutions Ltd
AU:JCS
|
0.778x |
|
Fiberweb (India) Limited
NSE:FIBERWEB
|
0.085x |
|
Praxis Home Retail Limited
NSE:PRAXIS
|
-0.206x |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2025. View Traws Pharma Inc (TRAW) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-629.00K | $-18.18 Million | 28.911x | +2969.46% |
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more